🚀Dr. Reddy's scores a first-mover advantage in the U.S. oncology market!

💊 The company has launched **Bosutinib Tablets 400mg**, the first generic version of **Bosulif®** in the United States. 🔹 First-to-market launch in the U.S. 🔹 Eligible for **180 days of generic exclusivity** 🔹 Exclusive U.S. marketing rights secured by Dr. Reddy's 🔹 Developed and manufactured in collaboration with MSN Laboratories 📈 With the branded drug recording approximately **US$253.8 million** in annual U.S. sales, this launch could further strengthen Dr. Reddy's oncology portfolio and U.S. generics business. Will this first-mover advantage translate into stronger earnings momentum for Dr. Reddy's? Share your thoughts below! 👇 👍 Like | 🔄 Share | ➕ Follow ⚠️ *Disclaimer: This post is for educational purposes only and not investment advice.* $DRREDDY